Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $25.35. The company's market cap stands at 144.1B, with a P/E ratio of 14.60 and a dividend yield of 6.8%.
On 2025-11-24, Pfizer(PFE) stock moved within a range of $25.03 to $25.46. With shares now at $25.35, the stock is trading +1.3% above its intraday low and -0.5% below the session's peak.
Trading activity shows a volume of 21.02M, compared to an average daily volume of 94.58M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Guggenheim raised the firm’s price target on Pfizer (PFE) to $35 from $33 and keeps a Buy rating on the shares. Pfizer’s acquisition of Metsera (MTSR) is “a wis...
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortuma...
TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...
Analyst ratings
56%
of 27 ratingsMore PFE News
Shares of Pfizer, Inc. (NASDAQ:PFE) are trading higher after a study found that the company’s new mRNA flu vaccine outperforms traditional shots against predomi...
Pfizer (PFE) and Astellas Pharma (ALPMY) (ALPMY announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed antibody-drug conj...
A Phase 3 study funded by Pfizer Inc. (NYSE:PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than tradit...
The drugmaker may not continue to lag the market for much longer. The past five years have been a roller-coaster ride for Pfizer (PFE 1.93%). The pharmaceutica...
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak. However, Pfizer’s non-COVID operational re...
Texas Attorney General Ken Paxton has secured a $41.5M settlement with Pfizer (PFE) and Tris Pharma for allegedly providing adulterated pharmaceutical drugs to...
The company's earnings fell by 21% last quarter. Healthcare giant Pfizer (PFE 0.60%) has been offering a high yield for some time. But that hasn't been enough...
